New evidence that tamoxifen does not induce osteoporosis: a nuclear activation analysis and absorptiometry study
- 1 May 1992
- journal article
- Published by Oxford University Press (OUP) in The British Journal of Radiology
- Vol. 65 (773) , 417-420
- https://doi.org/10.1259/0007-1285-65-773-417
Abstract
The possibility of increased risk for osteoporosis in breast cancer patients treated with tamoxifen was investigated. 26 patients aged 41-65 years without skeletal metastases were studied. All patients were treated with 20 mg/d tamoxifen for a mean time of 22 months. The data obtained by in vivo neutron activation analysis of the phosphorus content in hands, were supplemented with data obtained by single photon absorptiometry in the forearm and radiographic morphometry. Comparison of the data with that of age and sex matched normal controls showed that breast cancer patients treated with tamoxifen are not prone to osteoporosis.Keywords
This publication has 12 references indexed in Scilit:
- Concentration of Bone elements in osteoporosisJournal of Bone and Mineral Research, 1990
- Bone mineral content of women receiving tamoxifen for mastalgiaBritish Journal of Cancer, 1989
- Effects of Tamoxifen on Spinal Bone Density in Women With Breast CancerJNCI Journal of the National Cancer Institute, 1989
- Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two yearsBreast Cancer Research and Treatment, 1988
- Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in ratsJournal of Bone and Mineral Research, 1987
- Bone mineral content in early-postmenopausal and postmenopausal osteoporotic women: comparison of measurement methods.Radiology, 1986
- Involutional OsteoporosisNew England Journal of Medicine, 1986
- The effect of tamoxifen on bone mineral content in premenopausal women with breast cancerCancer, 1984
- Additive hormonal therapy in women with advanced breast cancerCancer, 1984
- Measurement of Bone Mineral in vivo: An Improved MethodScience, 1963